Kanzhun Analyst Price Targets - Benzinga

Kanzhun Ltd

BZNASDAQ

Trade with Public

Trade with Public

$16.21

-0.0499-0.31%

마지막 업데이트: Oct 22, 10:19 AM

$15.99

-0.27-1.66%

개요 뉴스 실적 전망 이벤트목표가재무 심리 지분 현황 배당금 비교 옵션 주식 보고서

Kanzhun Analyst Price Targets - Benzinga

Kanzhun Analyst Price Targets

Wall Street analyst price targets and consensus rating for Kanzhun (BZ).

Price Target Range — 11 Quarters

Analyst Consensus — 9 Analysts

8Buy

1Hold

Consensus RatingBuy# Analysts9Avg. Consensus PT$28Upside to Avg. PT+75.4%

Rating Trend — Last 9 Months

Recent Analyst Actions

모든 평가 보기 →

Date	Firm	Analyst	Action	Rating Change	Price Target
Aug 27, 2026	Barclays	Jiong Shao	PT Raise	Overweight	$19→$20
Aug 18, 2026	B of A Securities	Miranda Zhuang	Initiate	Neutral	$74
Jun 5, 2026	Bernstein	Robin Zhu	Upgrade	Market Perform→Outperform	$17→$18
Mar 20, 2026	Barclays	Jiong Shao	PT Cut	Overweight	$28→$19
Nov 19, 2025	Barclays	Jiong Shao	PT Raise	Overweight	$25→$28
Aug 22, 2025	Barclays	Jiong Shao	PT Raise	Overweight	$22→$25
Aug 21, 2025	UBS	Wei Xiong	Upgrade	Neutral→Buy	$26
Aug 20, 2025	Jefferies	Thomas Chong	PT Raise	Buy	$20→$24
Mar 13, 2025	Barclays	Jiong Shao	PT Raise	Overweight	$16→$22
Dec 9, 2024	Barclays	Jiong Shao	PT Raise	Overweight	$14→$16
Dec 9, 2024	Bernstein	Robin Zhu	Downgrade	Outperform→Market Perform	$19→$15
Nov 29, 2024	Citigroup	Brian Gong	PT Cut	Buy	$17→$16
Aug 30, 2024	Barclays	Jiong Shao	PT Cut	Overweight	$27→$14
May 22, 2024	UBS	Wei Xiong	PT Raise	Neutral	$22→$24
May 22, 2024	JP Morgan	Allen Li	PT Raise	Overweight	$23→$25
Mar 13, 2024	Barclays	Jiong Shao	PT Raise	Overweight	$22→$27
Mar 13, 2024	New Street Research	Jin Yoon	Upgrade	Neutral→Buy	$25
Mar 12, 2024	Macquarie	Danny Lee	Upgrade	Neutral→Outperform	—
Dec 20, 2023	New Street Research	Jin Yoon	Initiate	Neutral	$17
Dec 13, 2023	JP Morgan	Allen Li	Initiate	Overweight	$20

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Barclays Maintains Overweight on Kanzhun, Raises Price Target to $20

Barclays analyst Jiong Shao maintains Kanzhun (NASDAQ:BZ) with a Overweight and raises the price target from $19 to $20.

Benzinga Newsdesk

This Definium Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

Top analysts changed outlook on top names. See analyst ratings page for all changes.

Avi Kapoor

PRO
B of A Securities Initiates Coverage On Kanzhun with Neutral Rating, Announces Price Target of $74

B of A Securities analyst Miranda Zhuang initiates coverage on Kanzhun (NASDAQ:BZ) with a Neutral rating and announces Price Target of $74.

Benzinga Newsdesk

PRO
Bernstein Upgrades Kanzhun to Outperform, Raises Price Target to $18

Bernstein analyst Robin Zhu upgrades Kanzhun (NASDAQ:BZ) from Market Perform to Outperform and raises the price target from $16.5 to $18.

Benzinga Newsdesk

PRO
Barclays Maintains Overweight on Kanzhun, Lowers Price Target to $19

Barclays analyst Jiong Shao maintains Kanzhun (NASDAQ:BZ) with a Overweight and lowers the price target from $28 to $19.

Benzinga Newsdesk

PRO
Barclays Maintains Overweight on Kanzhun, Raises Price Target to $28

Barclays analyst Jiong Shao maintains Kanzhun (NASDAQ:BZ) with a Overweight and raises the price target from $25 to $28.

Benzinga Newsdesk